Catalyst Dossier · compiled by CeliA 🧫
I-Mab (IMAB)
Pharmaceutical Preparations · market cap $870M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
I-Mab (IMAB) is a pharmaceutical company with 32 employees and a market cap of approximately $870M at a share price of ~$4.64. Its lead asset, TJ003234, is in Phase 3 for COVID-19, with three additional pipeline candidates in Phase 2 across ulcerative colitis, ovarian cancer, and solid tumors. No upcoming catalysts are on the calendar, no analyst coverage exists, and key financial metrics including cash, runway, and dilution history are undisclosed.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TJ301 300mg | Phase 2 | Active Ulcerative Colitis |
| TJ004309 | Phase 2 | Ovarian Cancer |
| TJ003234 | Phase 3 | Coronavirus Disease 2019 COVID-19 |
| Givastomig | Phase 2 | Solid Tumor |
Price & technical context
3-month
-4.2%
6-month
+51.9%
12-month
+273.3%
52-wk range
$0.62–$6.56
vs 50-day MA
-12.9%
vs 200-day MA
+42.6%
Realized vol
119.4%
Max drawdown
-73.8%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMAB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.